Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes

Pediatric Blood and Cancer

Volumn 60, Issue 7, 2013, Pages 1095-1102

  Birks, Diane K ^a,b   Donson, Andrew M ^b,c   Patel, Purvi R ^b,c   Sufit, Alexandra ^b,c   Algar, Elizabeth M ^d,e   Dunham, Christopher ^f   Kleinschmidt Demasters, B K ^a   Handler, Michael H ^a,b   Vibhakar, Rajeev ^b,c   Foreman, Nicholas K ^b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

^c Children's Hospital Colorado   (United States)

^d MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Atypical teratoid rhabdoid tumor; INI 1; Kidney rhabdoid tumor; Microarray; SMARCB1

Indexed keywords

ARTICLE; BRAIN TUMOR; CELL CYCLE; CELL PROLIFERATION; CHILDHOOD CANCER; EPIGENETICS; GENE EXPRESSION; HUMAN; KIDNEY TUMOR; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RHABDOID TUMOR;

BRAIN NEOPLASMS; CELL CYCLE; CLUSTER ANALYSIS; EPIGENESIS, GENETIC; HUMANS; KIDNEY NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RHABDOID TUMOR; TRANSCRIPTOME;

EID: 84878242468     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24481     Document Type: Article

References (37)

1. Biegel JA, Tan L, Zhang F, et al. Alterations of the hsnf5/ini1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin Cancer Res 2002;8:3461-3467.
2. Judkins AR, Mauger J, Ht A, et al. Immunohistochemical analysis of hsnf5/ini1 in pediatric cns neoplasms. Am J Surg Pathol 2004;28:644-650.
3. Hilden JM. Central nervous system atypical teratoid/rhabdoid tumor: Results of therapy in children enrolled in a registry. J Clin Oncol 2004;22:2877-2884.
4. Garre ML, Tekautz T. Role of high-dose chemotherapy (hdct) in treatment of atypical teratoid/rhabdoid tumors (at/rts). Pediatr Blood Cancer 2010;54:647-648.
5. Chi SN, Zimmerman MA, Yao X, et al. Intensive multimodality treatment for children with newly diagnosed cns atypical teratoid rhabdoid tumor. J Clin Oncol 2009;27:385-389.
6. Gadd S, Sredni ST, Huang CC, et al. Rhabdoid tumor: Gene expression clues to pathogenesis and potential therapeutic targets. Lab Invest 2010;90:724-738.
7. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436-442.
8. Albanese P, Belin MD, elattre O. The tumour suppressor hsnf5/ini1 controls the differentiation potential of malignant rhabdoid cells. Eur J Cancer 2006;42:2326-2334.
9. Venneti S, Le P, Martinez D, et al. P16ink4a and p14arf tumor suppressor pathways are deregulated in malignant rhabdoid tumors. J Neuropathol Exp Neurol 2011;70:596-609.
10. Venneti S, Le P, Martinez D, et al. Malignant rhabdoid tumors express stem cell factors, which relate to the expression of ezh2 and id proteins. Am J Surg Pathol 2011;35:1463-1472.
11. Birks DK, Donson AM, Patel PR, et al. High expression of bmp pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival. Neuro Oncol 2011;13:1296-1307.
12. Dennis G, Jr., Sherman BT, Hosack DA, et al. David: Database for annotation, visualization, and integrated discovery. Genome Biol 2003;4:P3.
13. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using david bioinformatics resources. Nat Protoc 2009;4:44-57.
14. Thomas PD, Kejariwal A, Campbell MJ, et al. Panther: A browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res 2003;31:334-341.
15. Medjkane S, Novikov E, Versteege I, et al. The tumor suppressor hsnf5/ini1 modulates cell growth and actin cytoskeleton organization. Cancer Res 2004;64:3406-3413.
16. Isakoff MS, Sansam CG, Tamayo P, et al. Inactivation of the snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci USA 2005;102:17745-17750.
17. Chai J, Charboneau AL, Betz BL, et al. Loss of the hsnf5 gene concomitantly inactivates p21cip/waf1 and p16ink4a activity associated with replicative senescence in a204 rhabdoid tumor cells. Cancer Res 2005;65:10192-10198.
18. Zhang ZK, Davies KP, Allen J, et al. Cell cycle arrest and repression of cyclin d1 transcription by ini1/hsnf5. Mol Cell Biol 2002;22:5975-5988.
19. Ma HI, Kao CL, Lee YY, et al. Differential expression profiling between atypical teratoid/rhabdoid and medulloblastoma tumor in vitro and in vivo using microarray analysis. Childs Nerv Syst 2010;26:293-303.
20. Morozov A, Lee SJ, Zhang ZK, et al. Ini1 induces interferon signaling and spindle checkpoint in rhabdoid tumors. Clin Cancer Res 2007;13:4721-4730.
21. Allen JC, Judkins AR, Rosenblum MK, et al. Atypical teratoid/rhabdoid tumor evolving from an optic pathway ganglioglioma: Case study. Neurol Oncol 2006;8:79-82.
22. Chacko G, Chacko AG, Dunham CP, et al. Atypical teratoid/rhabdoid tumor arising in the setting of a pleomorphic xanthoastrocytoma. J Neurooncol 2007;84:217-222.
23. Dougherty MJ, Santi M, Brose MS, et al. Activating mutations in braf characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 2010;12:621-630.
24. Kleinschmidt-DeMasters BK, Birks DK, Aisner DL, et al. Atypical teratoid/rhabdoid tumor arising in a ganglioglioma: Genetic characterization. Am J Surg Pathol 2011;35:1894-1901.
25. Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, et al. Novel cell lines established from pediatric brain tumors. J Neurooncol 2012;107:269-280.
26. Shalaby T, von Bueren AO, Hurlimann ML, et al. Disabling c-myc in childhood medulloblastoma and atypical teratoid/rhabdoid tumor cells by the potent g-quadruplex interactive agent s2t1-6otd. Mol Cancer Ther 2010;9:167-179.
27. Wilson BG, Wang X, Shen X, et al. Epigenetic antagonism between polycomb and swi/snf complexes during oncogenic transformation. Cancer Cell 2010;18:316-328.
28. Crea F, Hurt EM, Farrar WL. Clinical significance of polycomb gene expression in brain tumors. Mol Cancer 2010;9:265.
29. Alimova I, Venkataraman S, Harris P, et al. Targeting the enhancer of zeste homologue 2 in medulloblastoma. Int J Cancer 2012;131:1800-1809.
30. Wagener N, Macher-Goeppinger S, Pritsch M, et al. Enhancer of zeste homolog 2 (ezh2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 2010;10:524.
31. Kia SK, Gorski MM, Giannakopoulos S, et al. Swi/snf mediates polycomb eviction and epigenetic reprogramming of the ink4b-arf-ink4a locus. Mol Cell Biol 2008;28:3457-3464.
32. Jaboin J, Wild J, Hamidi H, et al. Ms-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002;62:6108-6115.
33. Graham C. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res 2006;12:223-234.
34. Furchert SE, Lanvers-Kaminsky C, Juurgens H, et al. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007;120:1787-1794.
35. Algar EM, Muscat A, Dagar V, et al. Imprinted cdkn1c is a tumor suppressor in rhabdoid tumor and activated by restoration of smarcb1 and histone deacetylase inhibitors. PLoS ONE 2009;4:e4482.
36. Knipstein JA, Birks DK, Donson AM, et al. Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells. Neuro Oncol 2012;14:175-183.
37. Venkataraman S, Alimova I, Tello T, et al. Targeting aurora kinase a enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells. J Neurooncol 2012;107:517-526.